## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.0% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($100.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Abivax Shares Jump 7.17% Midday, Supported by Entry into Nasdaq Biotechnology Index**
- Source: idéal investisseur | 20251219T110936 | Bullish | Relevance: 100%
- Abivax shares rose 7.17% midday due to its upcoming inclusion in the Nasdaq Biotechnology Index, effective December 22, 2025. This move, along with positive clinical trial results for obefazimod and target price upgrades by American brokers, has boosted investor confidence and significantly increased the company's stock performance over the past year. Didier Blondel, CFO of Abivax, highlighted that this inclusion marks a significant milestone and enhances the company's visibility among international investors.

**2. Assessing Abivax (ENXTPA:ABVX) Valuation After Strong Year-To-Date Gains And Recent Pullback**
- Source: Simply Wall Street | 20251219T020935 | Bearish | Relevance: 100%
- ABIVAX Société Anonyme (ENXTPA:ABVX) has experienced a recent pullback but maintains strong year-to-date gains. The article examines its valuation, noting an overvalued Price to Book of 14.9x compared to industry averages and a DCF model suggesting extreme overvaluation at €13.91 versus its current €97.60. It questions whether the market is correctly pricing a breakthrough or if expectations are outpacing fundamentals, emphasizing potential risks given the company's losses.

**3. Abivax to be added to Nasdaq Biotechnology Index**
- Source: TipRanks | 20251218T220935 | Bullish | Relevance: 100%
- Abivax (ABVX) has announced its inclusion in the Nasdaq Biotechnology Index, effective before the market opens on Monday, December 22. This news comes alongside several analyst price target increases for ABVX, with targets ranging from $131 to $175, and a report of increased losses in Q3 2025 due to rising R&D costs. The addition to the index is often seen as a positive development, potentially increasing the company's visibility and liquidity.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Citizens | $131 | $114 | +15% |
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Citizens | main | Market Outperform |
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 721% YoY. Analyst sentiment positive (1 raises, avg +15%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.1B |
| Beta | -0.11 |
| 52W Range | $4.77 - $138.49 |
| Short Interest | 3.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -1.5% to -4.0% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). AM_20 at -3.7% indicates price below own 20MA trend. Underperforming sector by 3.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 2.20x) but short-term weakness (below SMA20). MACD histogram bearish (-1.77), momentum weakening. RSI neutral at 50. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.00% (CS: 15) | Weak |
| RSI_14 | 50.1 | Neutral |
| MACD Histogram | -1.77 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 1.063x | Above |
| vs SMA200 | 2.201x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $114.94
- **Stop Loss:** $100.28 (12.8% risk)
- **Target:** $129.60 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 81
- **Position Value:** $9,310.14
- **Portfolio %:** 9.31%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*